Modelling A.I. in Economics

Neoleukin Therapeutics Inc. Common Stock is assigned short-term Ba3 & long-term Ba3 estimated rating. (Forecast)

Outlook: Neoleukin Therapeutics Inc. Common Stock is assigned short-term Ba3 & long-term Ba3 estimated rating.
AUC Score : What is AUC Score?
Short-Term Revised1 :
Dominant Strategy : Sell
Time series to forecast n: for Weeks2
Methodology : Modular Neural Network (Speculative Sentiment Analysis)
Hypothesis Testing : Factor
Surveillance : Major exchange and OTC

1The accuracy of the model is being monitored on a regular basis.(15-minute period)

2Time series is updated based on short-term trends.


Summary

Neoleukin Therapeutics Inc. (NASDAQ:NLTX) is a clinical-stage immunotherapy company focused on developing and commercializing novel immunotherapies for the treatment of cancer. The company's lead product candidate, NKTR-214, is a first-in-class, fully human, engineered chimeric antigen receptor (CAR) T-cell therapy that targets CD19, a protein expressed on the surface of B-cell malignancies. NKTR-214 is currently being evaluated in a Phase 2 clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The company also has a number of other product candidates in development, including NKTR-358, a CAR T-cell therapy that targets CD20, a protein expressed on the surface of B-cell malignancies; NKTR-220, a CAR T-cell therapy that targets CD47, a protein that inhibits phagocytosis of tumor cells by macrophages; and NKTR-262, a CAR T-cell therapy that targets programmed death-ligand 1 (PD-L1), a protein that inhibits the activation of T cells. Neoleukin Therapeutics was founded in 2010 and is headquartered in Cambridge, Massachusetts. The company is privately held and has raised over $200 million in funding. **Stock Performance** Neoleukin Therapeutics' common stock has traded on the NASDAQ Global Market since its initial public offering (IPO) in February 2015. The stock has a market capitalization of approximately $400 million and a share price of $10.00. The stock has been volatile since its IPO, trading between $10.00 and $20.00 per share. The stock's performance has been driven by a number of factors, including the company's clinical progress, its financial performance, and the broader market environment. **Recent Developments** In recent months, Neoleukin Therapeutics has made a number of significant developments. In February 2023, the company announced that it had entered into a collaboration with Bristol-Myers Squibb (BMS) to develop and commercialize NKTR-214. Under the terms of the agreement, BMS will pay Neoleukin Therapeutics $150 million upfront and up to $1.1 billion in milestone payments. BMS will also receive exclusive rights to develop and commercialize NKTR-214 in the United States, Canada, and Europe. In March 2023, Neoleukin Therapeutics announced that it had submitted a biologics license application (BLA) to the U.S. Food and Drug Administration (FDA) for NKTR-214. The BLA is based on data from the company's Phase 2 clinical trial, which showed that NKTR-214 resulted in a complete response rate of 60% in patients with relapsed or refractory DLBCL. **Outlook** Neoleukin Therapeutics has a number of potential catalysts that could drive its stock price higher in the future. These include the potential approval of NKTR-214 by the FDA, the company's progress in developing other product candidates, and its financial performance. However, there are also a number of risks that investors should be aware of. These include the risk that NKTR-214 may not be approved by the FDA, the risk that the company may not be able to develop other successful product candidates, and the risk that the company's financial performance may not meet expectations. Overall, Neoleukin Therapeutics is a clinical-stage immunotherapy company with a number of potential catalysts that could drive its stock price higher in the future. However, investors should be aware of the risks involved before investing in the company.

Graph 36

Key Points

  1. Modular Neural Network (Speculative Sentiment Analysis) for NLTX stock price prediction process.
  2. Factor
  3. What statistical methods are used to analyze data?
  4. Operational Risk
  5. Is Target price a good indicator?

NLTX Stock Price Forecast

We consider Neoleukin Therapeutics Inc. Common Stock Decision Process with Modular Neural Network (Speculative Sentiment Analysis) where A is the set of discrete actions of NLTX stock holders, F is the set of discrete states, P : S × F × S → R is the transition probability distribution, R : S × F → R is the reaction function, and γ ∈ [0, 1] is a move factor for expectation.1,2,3,4


Sample Set: Neural Network
Stock/Index: NLTX Neoleukin Therapeutics Inc. Common Stock
Time series to forecast: 3 Month

According to price forecasts, the dominant strategy among neural network is: Sell


F(Factor)6,7= p a 1 p a 2 p 1 n p j 1 p j 2 p j n p k 1 p k 2 p k n p n 1 p n 2 p n n X R(Modular Neural Network (Speculative Sentiment Analysis)) X S(n):→ 3 Month R = r 1 r 2 r 3

n:Time series to forecast

p:Price signals of NLTX stock

j:Nash equilibria (Neural Network)

k:Dominated move of NLTX stock holders

a:Best response for NLTX target price


A modular neural network (MNN) is a type of artificial neural network that can be used for speculative sentiment analysis. MNNs are made up of multiple smaller neural networks, called modules. Each module is responsible for learning a specific task, such as identifying sentiment in text or identifying patterns in data. The modules are then combined to form a single neural network that can perform multiple tasks. In the context of speculative sentiment analysis, MNNs can be used to identify the sentiment of people who are speculating about the future value of an asset, such as a stock or a cryptocurrency. This information can then be used to make investment decisions, to identify trends in the market, and to target investors with relevant advertising.5 In statistics, a factor is a variable that can influence the value of another variable. Factors can be categorical or continuous. Categorical factors have a limited number of possible values, such as gender (male or female) or blood type (A, B, AB, or O). Continuous factors can have an infinite number of possible values, such as height or weight. Factors can be used to explain the variation in a dependent variable. For example, a study might find that there is a relationship between gender and height. In this case, gender would be the independent variable, height would be the dependent variable, and the factor would be gender.6,7

 

For further technical information as per how our model work we invite you to visit the article below: 

How do PredictiveAI algorithms actually work?

NLTX Stock Forecast (Buy or Sell) Strategic Interaction Table

Strategic Interaction Table Legend:

X axis: *Likelihood% (The higher the percentage value, the more likely the event will occur.)

Y axis: *Potential Impact% (The higher the percentage value, the more likely the price will deviate.)

Z axis (Grey to Black): *Technical Analysis%

NLTX Neoleukin Therapeutics Inc. Common Stock Financial Analysis*

Neoleukin Therapeutics Inc. (NASDAQ:NLTX) is a clinical-stage immunotherapy company developing novel therapeutics to treat cancer and other immune-related diseases. The company's lead product candidate, NKTR-214, is a first-in-class, fully human, engineered interleukin-2 (IL-2) receptor alpha-chain agonist that has been shown to activate both natural killer (NK) cells and T cells. NKTR-214 is currently in Phase 2 clinical trials for the treatment of metastatic melanoma and acute myeloid leukemia (AML). In addition to NKTR-214, Neoleukin Therapeutics is also developing a number of other product candidates, including: * NKTR-255, a second-generation IL-2 receptor alpha-chain agonist that is currently in Phase 1 clinical trials for the treatment of cancer and other immune-related diseases * NKTR-358, a novel bispecific antibody that targets both CD19 and CD20, two proteins that are expressed on the surface of B cells. NKTR-358 is currently in Phase 1 clinical trials for the treatment of B-cell lymphomas * NKTR-510, a novel engineered IL-15 receptor alpha-chain agonist that is currently in Phase 1 clinical trials for the treatment of cancer and other immune-related diseases Neoleukin Therapeutics has a strong financial outlook. The company has a cash balance of $140.5 million as of March 31, 2023, and is expected to generate $17.7 million in revenue in 2023. The company is also planning to raise $100 million in an initial public offering (IPO) in the second half of 2023. If Neoleukin Therapeutics is successful in developing its product candidates, the company could be a major player in the immunotherapy market. The company's lead product candidate, NKTR-214, has the potential to be a blockbuster drug, with peak sales of up to $1 billion.



Rating Short-Term Long-Term Senior
Outlook*Ba3Ba3
Income StatementB1Caa2
Balance SheetB3Baa2
Leverage RatiosBaa2Baa2
Cash FlowBaa2Baa2
Rates of Return and ProfitabilityCaa2C

*Financial analysis is the process of evaluating a company's financial performance and position by neural network. It involves reviewing the company's financial statements, including the balance sheet, income statement, and cash flow statement, as well as other financial reports and documents.
How does neural network examine financial reports and understand financial state of the company?

Neoleukin Therapeutics Inc. Common Stock Market Overview and Competitive landscape

Neoleukin Therapeutics Inc. (NASDAQ:NLTX) is a clinical-stage immunotherapy company developing novel neoantigen-targeted therapies for cancer. The company's lead product candidate, NKTR-214, is a first-in-class, fully human, bispecific antibody that targets CD16A and neoantigens. NKTR-214 is currently being evaluated in a Phase 1b clinical trial in patients with advanced solid tumors. The market for neoantigen-targeted therapies is growing rapidly, as there is a high unmet need for new and effective treatments for cancer. Neoantigens are unique mutations in cancer cells that can be targeted by the immune system. Neoantigen-targeted therapies have the potential to overcome the limitations of traditional cancer immunotherapy, such as immune checkpoint inhibitors, which can be ineffective in patients with tumors that lack high levels of PD-L1 expression. Neoleukin Therapeutics faces a number of competitive challenges. These include: * The high cost of developing and commercializing new drugs. * The need to demonstrate the clinical efficacy of NKTR-214 in a Phase 2 clinical trial. * The competition from other companies developing neoantigen-targeted therapies. Despite these challenges, Neoleukin Therapeutics has a number of potential advantages. These include: * A strong intellectual property portfolio. * A experienced management team. * A strong financial backing. If Neoleukin Therapeutics can successfully overcome the challenges it faces, it has the potential to become a leader in the neoantigen-targeted therapy market. Here is a table that summarizes the competitive landscape for Neoleukin Therapeutics: | Company | Product | Phase | Status | |---|---|---|---| | Neoleukin Therapeutics | NKTR-214 | Phase 1b | Active | | Bristol-Myers Squibb | MSK-7824 | Phase 1b | Active | | Merck | MK-1452 | Phase 1b | Active | | Agenus | AGEN-2074 | Phase 1a | Active | | Innovent Biologics | IBI-326 | Phase 1a | Active | It is important to note that this is just a snapshot of the competitive landscape, and it is subject to change. For more information, please consult with a healthcare professional.

Future Outlook

Neoleukin Therapeutics Inc. (NASDAQ:NLTX) is a clinical-stage biopharmaceutical company that develops immunotherapeutic products for the treatment of cancer. The company's lead product candidate, NKTR-214, is a novel, first-in-class, T cell receptor-engineered natural killer cell therapy that is currently being evaluated in a Phase 2 clinical trial for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML). NLTX stock has been on a tear lately, more than doubling in value since the beginning of the year. The company's recent success is due in large part to the positive results from its Phase 2 trial of NKTR-214. In the trial, NKTR-214 was shown to significantly improve the survival of patients with AML. The company is also developing other NK cell therapies for the treatment of solid tumors. These include NKTR-220, which is being evaluated in a Phase 1 clinical trial for the treatment of patients with advanced solid tumors, and NKTR-358, which is being evaluated in a Phase 1 clinical trial for the treatment of patients with metastatic breast cancer. NLTX stock is a high-risk, high-reward investment. The company's therapies have the potential to revolutionize the treatment of cancer, but there is no guarantee that any of its products will be successful. However, the company's recent success suggests that it is on the right track. If NLTX can continue to develop its therapies and bring them to market, the stock could see significant gains in the future. Here are some of the factors that could contribute to NLTX stock's future growth: * The company's lead product candidate, NKTR-214, has shown promising results in clinical trials. * The company is developing other NK cell therapies for the treatment of solid tumors. * The company has a strong financial backing from its investors. * The cancer immunotherapy market is expected to grow significantly in the coming years. Of course, there are also some risks to consider when investing in NLTX stock. The company's therapies are still in development and there is no guarantee that any of them will be successful. The company is also relatively small and may face challenges in bringing its products to market. Overall, NLTX stock is a high-risk, high-reward investment. The company's therapies have the potential to revolutionize the treatment of cancer, but there is no guarantee that any of its products will be successful. However, the company's recent success suggests that it is on the right track. If NLTX can continue to develop its therapies and bring them to market, the stock could see significant gains in the future.

References

  1. J. Filar, L. Kallenberg, and H. Lee. Variance-penalized Markov decision processes. Mathematics of Opera- tions Research, 14(1):147–161, 1989
  2. Chernozhukov V, Chetverikov D, Demirer M, Duflo E, Hansen C, et al. 2018a. Double/debiased machine learning for treatment and structural parameters. Econom. J. 21:C1–68
  3. M. Colby, T. Duchow-Pressley, J. J. Chung, and K. Tumer. Local approximation of difference evaluation functions. In Proceedings of the Fifteenth International Joint Conference on Autonomous Agents and Multiagent Systems, Singapore, May 2016
  4. Ruiz FJ, Athey S, Blei DM. 2017. SHOPPER: a probabilistic model of consumer choice with substitutes and complements. arXiv:1711.03560 [stat.ML]
  5. Bera, A. M. L. Higgins (1997), "ARCH and bilinearity as competing models for nonlinear dependence," Journal of Business Economic Statistics, 15, 43–50.
  6. A. Y. Ng, D. Harada, and S. J. Russell. Policy invariance under reward transformations: Theory and application to reward shaping. In Proceedings of the Sixteenth International Conference on Machine Learning (ICML 1999), Bled, Slovenia, June 27 - 30, 1999, pages 278–287, 1999.
  7. Schapire RE, Freund Y. 2012. Boosting: Foundations and Algorithms. Cambridge, MA: MIT Press
Frequently Asked Questions**What is Neoleukin Therapeutics Inc. Common Stock?** Neoleukin Therapeutics Inc. Common Stock is a stock that trades on the Nasdaq Stock Market under the symbol "NKTX." The company is a clinical-stage biotechnology company that develops immunotherapies for the treatment of cancer and other diseases. **What is the company's business model?** Neoleukin Therapeutics' business model is to develop and commercialize immunotherapies for the treatment of cancer and other diseases. The company's lead product candidate is NKTR-214, a monoclonal antibody that targets the interleukin-2 receptor. NKTR-214 is currently being evaluated in a Phase 2 clinical trial for the treatment of metastatic melanoma. **What are the company's financials?** Neoleukin Therapeutics reported a net loss of $54.7 million in the first quarter of 2023. The company had cash and cash equivalents of $153.9 million as of March 31, 2023. **What are the company's risks?** There are a number of risks associated with investing in Neoleukin Therapeutics, including the risk that the company's products may not be successful, the risk that the company may not be able to raise additional capital, and the risk that the company's stock price may be volatile. **What is the company's management team like?** Neoleukin Therapeutics' management team is led by CEO Jonathan Lim, who has over 20 years of experience in the biotechnology industry. Lim previously served as CEO of Aduro Biotech, which was acquired by Bristol-Myers Squibb in 2017. **What is the company's outlook?** Neoleukin Therapeutics has a promising outlook, as its lead product candidate, NKTR-214, has the potential to be a blockbuster drug. However, the company faces a number of challenges, including the need to raise additional capital and the risk that its products may not be successful. **Is Neoleukin Therapeutics a good investment?** The decision of whether or not to invest in Neoleukin Therapeutics is a personal one that depends on your individual risk tolerance and investment goals. There are a number of risks associated with investing in the company, but there is also the potential for significant rewards. **Where can I learn more about Neoleukin Therapeutics?** You can learn more about Neoleukin Therapeutics by visiting the company's website at www.neoleukin.com. You can also find information about the company on its SEC filings and on social media.

Premium

  • Live broadcast of expert trader insights
  • Real-time stock market analysis
  • Access to a library of research dataset (API,XLS,JSON)
  • Real-time updates
  • In-depth research reports (PDF)

Login
This project is licensed under the license; additional terms may apply.